Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or t

Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, de

IMA401 achieved deep and durable responses in various indications, including melanoma and head and n

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expans

Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggere

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co

Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or

Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Hei

SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ: IMTX) in the fou

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have earned a consensus recommendation of "

Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a rob

Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price traded down 5% on Friday. The stock tra

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been given an average recommendation o

Immatics N.V. (NASDAQ: IMTX - Get Free Report) shot up 3.9% on Wednesday. The stock traded as high a

  On Wednesday, 807 companies reached new 52-week lows.